Valneva SE (VALN) reports Q1 2026 earnings with €30.5M in sales, restructuring plan, and adjusted guidance. Learn more about the financial outlook.

Key Takeaways

• Product sales decreased to €30.5 million in Q1 2026 from €48.6 million in Q1 2025, primarily due to supply phasing with the U.S. Department of Defense.
• The company reported a net loss of €32.1 million for the quarter compared to a loss of €9.2 million in the previous year.
• Cash and cash equivalents at the end of March 2026 stood at €105 million, down from €110 million a year prior.
• Guidance for fiscal year 2026 was adjusted to €135-150 million in product sales and €145-160 million in total revenues.
• A global workforce reduction of 10-15% is expected as part of a restructuring plan aimed at cutting operating expenses by 25-35%.

Financial Performance

Valneva SE reported its Q1 2026 financial results amid considerable challenges. The company's product sales totaled €30.5 million, a significant decline compared to €48.6 million in the same quarter of 2025. This decline can be primarily attributed to the phasing of deliveries to the U.S. Department of Defense, which is Valneva's largest customer for its Xiaro vaccine. The sales figures for Xiaro dropped to €20.2 million from €27.5 million year-over-year, while Ducoral sales fell from €12.3 million to €8.6 million, affected by a change in distribution partners in key markets like Germany.

The total revenues for the quarter reached €30.9 million, down from €49.2 million in Q1 2025. The gross margin for commercial product sales excluding Ixchig was reported at 45.2%, sharply lower than 62.7% in the same period last year. The increase in production costs, particularly related to the completion of the manufacturing transition to the new Almeida facility, along with higher batch write-offs, adversely impacted profitability. The operating loss for Q1 2026 was €23.7 million, up from the previous year's loss of €9 million.

Strategic Initiatives

Despite the financial setbacks, the company remains focused on advancing its research and development (R&D) initiatives. Valneva is actively involved in a pilot vaccination campaign in Brazil, aiming to vaccinate over 100,000 adults against Chikungunya. To date, more than 30,000 individuals have already received the vaccine. The company is also developing a tetravalent vaccine candidate against Shigellosis, targeting the four most common pathogenic Shigella bacteria. Two studies are currently ongoing, with readouts expected over the summer.

In response to the challenging market conditions, Valneva has initiated a restructuring plan aimed at streamlining operations and focusing resources on key projects. This plan includes a global workforce reduction of 10-15% and is expected to result in an overall reduction of operating expenses by 25-35% compared to 2025 levels.

Future Outlook

Looking ahead, Valneva has adjusted its guidance for fiscal year 2026, anticipating product sales of €135-150 million and total revenues of €145-160 million. Management has acknowledged the uncertainty surrounding vaccine uptake due to geopolitical factors affecting travel, which has been a significant driver of their sales. The company remains cautious about the potential impact of these external factors on its performance for the remainder of the year.

Despite these challenges, Valneva is optimistic about the prospects of its Lyme vaccine candidate, currently under review by Pfizer. Management expressed confidence that successful outcomes in this area could present significant strategic growth opportunities for the company. The focus will be on expanding the R&D pipeline beyond vector-borne diseases and optimizing operations to maximize cash generation from the commercial business.